EUCTR2016-000767-17-IT进行中（未招募）1 期
A randomized phase II trial of captem or folfiri as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study) - SENECA
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS0 个研究点目标入组 112 人开始时间: 2018年9月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 112
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Histopathologic diagnosis of neuroendocrine carcinomas (GEP NEC and lung NEC), G3 with ki67 > 20%.
- •2.Male or Female, aged >=18 years.
- •3.Measurable disease according to RECIST 1.1 criteria.
- •4.Patients already received a first line treatment for metastatic disease with platinum compound–based regimen chemotherapy (Cisplatin/Carboplatin and etoposide; folfox4 or capox).
- •5.Life expectancy greater than 3 months
- •6.ECOG performance status = 2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 42
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •1.Ki67< 20%.
- •2.Patients with metastatic NECs already treated with irinotecan regimen.
- •3.Patients with a known hypersensitivity to fluorouracil or calcio levofolinato or Irinotecan or their recipients.
- •4.All acute toxic effects of any prior therapy (including surgery radiation therapy, chemotherapy) must have resolved to a grade <= 1 according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE).
- •5.Life expectancy minor than 3 months.
- •6.ECOG performance status >2.
研究者
相似试验
进行中（未招募）
2 期
ImmunoTACEHepacellular CarcinomaLiverCancerISRCTN11889464niversity of Birmingham (UK)48
进行中（未招募）
1 期
A study comparing the standard treatment of transarterial chemoembolisation (TACE)plus low doses of chemotherapy (cyclophosphamide) with an immune cell derived vaccineHepatocellular carcinomaEUCTR2011-001690-62-GBniversity of Birmingham48
已完成
不适用
Phase II randomized clinical trial for the purpose of examining the protective efficacy of the non-alcoholic fatty liver development by pancrelipase preparation being given for pancreatic cancer patients who underwent pancreaticoduodenectomy or total pancreatectomy.To assume the decreased rate of post-operative non-alcoholic fatty liver incidence in pancreatic cancer patients with the prophylactic administration of the pancrelipase preparation.JPRN-UMIN000019817Department of Surgery, Kansai Medical University80
招募中
不适用
Phase II clinical trial for the effectiveness and safety of AW-PD01 (helium / oxygen mixed gas) for respiratory failure in children and infants with airway stenotic lesions: Single facility single group open label intervention studyRespiratory failure, BronchiolitisJPRN-UMIN000025065Tokyo Metropolitan Children's Medical Center10
进行中（未招募）
不适用
An efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapyocally advanced (unresectable) or metastatic adenocarcinoma of the gastric and gastro-esophageal junctionMedDRA version: 16.0Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10030137Term: Oesophageal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000853-22-DEBristol-Myers Squibb International Corporation152